相关实验视频

Updated: Jul 16, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

在COVID-19后MS复发和恶化的风险:系统性审查和元分析

Homa Seyedmirzaei¹, Dorsa Salabat², Sara KamaliZonouzi²

¹Universal Scientific Education and Research Network (USERN), Tehran, Iran; Sports Medicine Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran; Interdisciplinary Neuroscience Research Program (INRP), Tehran University of Medical Sciences, Tehran, Iran.

Multiple sclerosis and related disorders

|February 5, 2024

概括

在多发性硬化症 (MS) 患者中,COVID-19感染不会增加复发或临床恶化的风险. 这一发现为SARS-CoV-2对多发性硬化症患者的影响提供了清晰度.

科学领域:

神经学神经学
传染性疾病传染性疾病
免疫学免疫学免疫学

背景情况:

上呼吸道病毒感染是多发性硬化症 (MS) 复发的潜在触发因素.
关于SARS-CoV-2对MS复发和疾病进展的具体影响仍在争论中.

研究的目的:

系统地评估COVID-19感染和MS复发率之间的关联.
评估COVID-19对MS患者临床残疾进展的影响,通过扩展残疾状态量表 (EDSS) 来衡量.

主要方法:

在主要的科学数据库 (PubMed,Scopus,Embase,Cochrane,Web of Science) 中进行全面的系统搜索.
包括14项研究进行系统审查和元分析.
包括元分析,子组分析,元回归和灵敏度分析在内的统计分析,以评估异质性和变化来源.

主要成果:

分析显示,COVID-19后复发率没有统计显著增加 (RR:0.97,95% CI:0.671.41,p=0.87).
根据EDSS (SMD: -0.09,95%CI: -0.220.03,p=0.13) 测量,COVID-19和残疾恶化之间没有发现显著的关联.
在EDSS变化分析中观察到显著的异质性 (I2=55%,p=0.01).

结论:

COVID-19感染与MS患者复发风险较高无关.
在MS患者中,SARS-CoV-2似乎不会导致临床恶化.

关键词:

在 COVID-19 疫情中,在EDSS中使用EDSS.多发性硬化症是多发性硬化症.复发复发的情况这就是SARS-CoV-2病毒.

更多相关视频

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

相关概念视频

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...